Current Report Filing (8-k)
December 16 2021 - 09:17AM
Edgar (US Regulatory)
0001704287 false 0001704287 2021-12-16
2021-12-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF
1934
DATE OF
REPORT (DATE OF EARLIEST EVENT REPORTED):
December 16, 2021
Bluejay Diagnostics, Inc.
(Exact Name
of Registrant as Specified in its Charter)
|
delaware |
|
001-41031 |
|
47-3552922 |
(State or
Other Jurisdiction of
Incorporation or Organization) |
|
(Commission
File No.) |
|
(I.R.S.
Employer
Identification No.) |
360 Massachusetts Avenue,
Suite 203
Acton,
MA
01720
(Address of
principal executive offices and zip code)
(844)
327-7078
(Registrant’s telephone
number, including area code)
(Former name
or former address, if changed from last report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General
Instruction A.2. below):
|
☐ |
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-14(c)). |
Indicate by
check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
Securities
registered pursuant to Section 12(b) of the Act:
|
Title of
each class |
|
Trading
Symbol (s) |
|
Name of
each exchange on which registered |
|
Common Stock, par value $0.0001 per share |
|
BJDX |
|
The
NASDAQ Stock Market LLC |
Item 2.02
Results of Operations and Financial Condition.
On December
16, 2021, Bluejay Diagnostics, Inc. (the “Company”) issued a press
release announcing its financial results for the quarter ended
September 30, 2021 and a corporate update. A copy of the press
release is attached to this report as Exhibit 99.1 and is
incorporated by reference herein.
Item
9.01. Financial Statements and Exhibits
SIGNATURE
Pursuant to
the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| |
Bluejay Diagnostics
Inc. |
| |
|
|
| |
By: |
/s/ Gordon
Kinder |
| |
|
Gordon
Kinder |
| |
|
Chief
Financial Officer |
| Dated:
December 16, 2021 |
|
|
2
Bluejay Diagnostics (NASDAQ:BJDX)
Historical Stock Chart
From Jun 2022 to Jul 2022
Bluejay Diagnostics (NASDAQ:BJDX)
Historical Stock Chart
From Jul 2021 to Jul 2022
